Endometrial Cancer
Conditions
Brief summary
The incidence of endometrial cancer (EC) is increasing .Different risk classifications are used to direct the primary and adjuvant therapy. The European Society for Medical Oncology - European Society of Gynaecological Oncology -European Society for Radiotherapy & Oncology (ESMO-ESGO- ESTRO) could guide the need for lymph node surgery pre-operatively, and also post-operatively to determine adjuvant treatment. Low-risk patients are managed with surgery alone, while higher-risk group patients undergo more aggressive surgical options. So, it is important to identify new prognostic markers for better stratification of patients to avoid under- or over treatment of EC patients.
Interventions
DIAGNOSTIC_TESTTissue Biopsy
The Post-hysterectomy tissue biopsy was analyzed immunohistochemically for detection of estrogen and progesterone receptors, P53 and L1CAM
Sponsors
Zagazig University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
36 Years to 72 Years
Healthy volunteers
No
Inclusion criteria
* aged 36 -72 years; * Previously diagnosed with endometrial carcinoma; * Histological Type of the tumor; * Myometrial Invasion; * lymph Node Invasion; * Cervical Invasion; * Biomarkers expression.
Exclusion criteria
* Lack of tumor tissue in tissue block
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| expression levels of p53/L1CAM/ER/PR | 36 Months | The Prognostic value of immunohistochemical detection of expression levels of p53/L1CAM/ER/PR in relation to ESMO-ESGO-ESTRO risk groups |
Countries
Egypt
Outcome results
None listed